Trials / Unknown
UnknownNCT05419674
Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection
Ten-day Amoxicillin-containing Dual Therapy as First-line Helicobacter Pylori Treatment in Elderly Patients: a Randomized Trial
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 393 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 60 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy of dual therapy compared with bismuth-containing quadruple therapy as first-line treatment for Helicobacter Pylori eradication, as well as the safety and economic benefits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vonoprazan | Potassium-competitive acid blocker |
| DRUG | Rabeprazole | Proton pump inhibitor |
| DRUG | Amoxicillin | Antibiotic for H. pylori eradication |
| DRUG | Clarithromycin | Antibiotic for H. pylori eradication |
| DRUG | Colloidal bismuth pectin | Gastric mucosal protective drug with anti-H. pylori effect |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
- First posted
- 2022-06-15
- Last updated
- 2023-02-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05419674. Inclusion in this directory is not an endorsement.